Davis's Lab & Diagnostic Tests
Alzheimer Disease Markers
To view the entire topic, please log in or purchase a subscription.
Nursing Central is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
General
Synonym/Acronym:
CSF tau protein and Beta-amyloid-42, AD, APP, PS-1, PS-2, ApoE4.
Rationale
To assist in evaluating for Alzheimer disease risk.
Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction.
Normal Findings
(Method: Electrochemiluminescent immunoassay for Beta-amyloid-42 and tau protein, and polymerase chain reaction for detection of apolipoprotein E2, E3, E4 alleles as biochemical and genetic markers of Alzheimer disease [AD] risk. Scientific studies indicate that a combination of elevated tau protein and decreased Beta-amyloid-42 protein levels are consistent with the presence of AD.)
| Beta-amyloid-42 | Greater than 1026 pg/mL (these levels correlate with negative findings in an amyloid PET scan) | ||||||||||||||||||||||||||||||||||||||||
| Tau protein (total) | Less than or equal to 238 pg/mL | ||||||||||||||||||||||||||||||||||||||||
| Phospho-Tau | Less than or equal to 21.7 pg/mL | ||||||||||||||||||||||||||||||||||||||||
| ApoE 2–4 alleles | Homozygous Apo e3 (e3/e3) is the most commonly identified (normal) pattern; the ApoE4 allele is associated with increased risk of developing AD | ||||||||||||||||||||||||||||||||||||||||
| The testing laboratory should be consulted for interpretation of results. | |||||||||||||||||||||||||||||||||||||||||
Critical Findings and Potential Interventions
N/A
-- To view the remaining sections of this topic, please log in or purchase a subscription --
General
Synonym/Acronym:
CSF tau protein and Beta-amyloid-42, AD, APP, PS-1, PS-2, ApoE4.
Rationale
To assist in evaluating for Alzheimer disease risk.
Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction.
Normal Findings
(Method: Electrochemiluminescent immunoassay for Beta-amyloid-42 and tau protein, and polymerase chain reaction for detection of apolipoprotein E2, E3, E4 alleles as biochemical and genetic markers of Alzheimer disease [AD] risk. Scientific studies indicate that a combination of elevated tau protein and decreased Beta-amyloid-42 protein levels are consistent with the presence of AD.)
| Beta-amyloid-42 | Greater than 1026 pg/mL (these levels correlate with negative findings in an amyloid PET scan) | ||||||||||||||||||||||||||||||||||||||||
| Tau protein (total) | Less than or equal to 238 pg/mL | ||||||||||||||||||||||||||||||||||||||||
| Phospho-Tau | Less than or equal to 21.7 pg/mL | ||||||||||||||||||||||||||||||||||||||||
| ApoE 2–4 alleles | Homozygous Apo e3 (e3/e3) is the most commonly identified (normal) pattern; the ApoE4 allele is associated with increased risk of developing AD | ||||||||||||||||||||||||||||||||||||||||
| The testing laboratory should be consulted for interpretation of results. | |||||||||||||||||||||||||||||||||||||||||
Critical Findings and Potential Interventions
N/A
There's more to see -- the rest of this topic is available only to subscribers.
